Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, single center study on radium‑223 dichloride in patients with castration‑resistant prostate cancer

Trial Profile

Prospective, single center study on radium‑223 dichloride in patients with castration‑resistant prostate cancer

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2018 New trial record
    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top